{"id":"W4281680466","doi":"10.1200/jco.2022.40.16_suppl.tps8601","title":"TRUST-II: A global phase II study for taletrectinib in <i>ROS1</i> fusion–positive lung cancer and other solid tumors.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"ROS1; Medicine; Crizotinib; Pemetrexed; Lung cancer; Internal medicine; Cohort; Oncology; Retrospective cohort study; Cancer; Chemotherapy; Adenocarcinoma; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002977009,0.002034609,0.001549086,0.0005246031,0.0005039575,0.001174257,0.001382612,0.001826001,0.005887406],"category_scores_gemma":[0.0007902842,0.0007127574,0.001977311,0.0006481684,0.0008437097,0.001110906,0.0008351181,0.003279151,0.002524116],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001973646,"about_ca_system_score_gemma":0.003269786,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001769761,"about_ca_topic_score_gemma":0.006185971,"domain_scores_codex":[0.9993353,0.0002584229,0.00003729043,0.000110791,0.00009356235,0.0001645647],"domain_scores_gemma":[0.9992447,0.00003336972,0.0001720486,0.00006262888,0.00009559213,0.0003917379],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.475782,0.07810252,0.02892477,0.00369952,0.003828786,0.0009096445,0.0005583434,0.004063126,0.2112172,0.001509667,0.06561711,0.1257873],"study_design_scores_gemma":[0.6025339,0.3028055,0.03548341,0.0001962849,0.001979224,0.00185944,0.0002197085,0.002248619,0.01541299,0.000543607,0.0366017,0.0001155823],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9293104,0.00684702,0.003919978,0.002997118,0.0004875728,0.02207581,0.02199293,0.0008210822,0.01154812],"genre_scores_gemma":[0.8969655,0.005063002,0.007579261,0.006383026,0.0003182571,0.02151393,0.05081563,0.000363989,0.0109975],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005887406,"threshold_uncertainty_score":0.0196954,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06680034650621461,"score_gpt":0.5470637216356914,"score_spread":0.4802633751294768,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}